Blueprint Medicines — Investor Presentation (January 2017)
31 slides from Blueprint Medicines's investor presentation, Jan 9, 2017
Slide 1: Revolutionizing the Development of Targeted Medicines for the Treatment of Serious Diseases
Revolutionizing the Development of Targeted Medicines for the Treatment of Serious Diseases January 2017
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
Slide 3: Successful execution in 2016 establishes momentum for 2017
Successful execution in 2016 establishes momentum for 2017 3 Clinical Development Achieved proof-of-concept in 3 lead clinical trials in 4 patient populations Filed IND for BLU-667 in RET Discovery Disclosed new PRKACA discovery program Initiated new wholly-owned and partnered programs Corporate Mai
Slide 4: 2017: Blueprint Medicines' vision becoming realized
2017: Blueprint Medicines’ vision becoming realized DATA MATURING AND EXPANDING DEVELOPMENT BLU-285: plan to present updated data in advanced GIST and SM, initiate new studies BLU-554: plan to present updated data in advanced HCC ESTABLISH REGISTRATION PATHWAY Interactions with global regulatory aut
Slide 5: Potential 2017 milestones
Potential 2017 milestones 5 Program Milestone BLU-285 GIST Update data from dose escalation in PDGFRα-driven advanced GIST* Update data from dose escalation in KIT-driven advanced GIST* Initiate expansion stage of Phase 1 study* Explore expedited clinical development pathways with regulatory authori
Slide 6: Innovative science and talented people drive Blueprint Medicines
Innovative science and talented people drive Blueprint Medicines Pursuing expedited pathways to deliver new treatments Broad diversified pipeline Building a sustainable company Differentiated approach to oncology Unique validated discovery engine Sustained research productivity rapidly adding innova
Slide 7: Unparalleled discovery platform that rapidly advances drug candidates
Unparalleled discovery platform that rapidly advances drug candidates 7 Kinome illustration reproduced courtesy of CSTI (cellsignal.com). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content. Target discovery engine unique compound library Highly se
Slide 8: Robust pipeline of diverse clinical-stage assets
Robust pipeline of diverse clinical-stage assets FLC, Fibrolamellar carcinoma; GIST, advanced gastrointestinal stromal tumors; NSCLC, non-small cell lung cancer All Phase 1 studies are in advanced disease 8 compound Discovery Preclinical Clinical Commercial rights BLU-285 Inhibitor of PDGFRα D842V a
Slide 9: Leveraging our scientific platform in collaborations
Leveraging our scientific platform in collaborations Undisclosed kinase target in a rare genetic disease Blueprint responsible for discovery and preclinical development Up to $250M in milestones* Rare Genetic Disease Expertise Cancer Immunology Expertise 9 Up to 5 small-molecule therapeutics targeti
Slide 10: BLU-554 Phase 1 Study in Advanced Hepatocellular Carcinoma (HCC)
BLU-554 Phase 1 Study in Advanced Hepatocellular Carcinoma (HCC)
Slide 11: Liver cancer is 2nd leading cause of cancer death worldwide
2 Liver cancer is 2nd leading cause of cancer death worldwide 1 Sorafenib used first line with a response rate ~2%; median time to progression 3-6 months Abnormally activated FGFR4 pathway in ~30% of patients enables biomarker driven patient selection Encouraging single agent activity in heavily pre
Slide 12: BLU-554 Phase 1 study design in advanced hepatocellular carcinoma
BLU-554 Phase 1 study design in advanced hepatocellular carcinoma Next steps Assessment of response by FGF19 expression sub-type Planning to increase cohort sizes and evaluate BID dosing Evaluation of additional development options, including opportunities to move to earlier lines of therapy and com
Slide 13: Proof-of-concept established for highly selective targeting of FGFR4 with BLU-554 in advanced HCC
Proof-of-concept established for highly selective targeting of FGFR4 with BLU-554 in advanced HCC 13 AE, adverse event; DLT, dose limiting toxicity; IHC, immunohistochemistry; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable
Slide 14: BLU-285 Phase 1 Study in Advanced Gastrointestinal Stromal Tumors (GIST)
BLU-285 Phase 1 Study in Advanced Gastrointestinal Stromal Tumors (GIST)
Slide 15: Advanced GIST is a rare sarcoma of the GI tract
Advanced GIST is a rare sarcoma of the GI tract BSC, best supportive care; GI, gastrointestinal; ORR, objective response rate; PFS, progression-free survival. Cassier (2012) CCR;18:4458; Yoo (2016) Can Res Treat; 48:546; Corless (2005) JCO;23:5357; Barnett and Heinrich (2012) Am Soc Clin Onc Ed Book
Slide 16: Activating receptor tyrosine kinase mutations drive metastatic GIST
Activating receptor tyrosine kinase mutations drive metastatic GIST 16 Prevalence Resistance mutation Primary Secondary KIT Exon 17 ~ 1% 2L ~ 20% 3L ~ 90% PDGFR D842V ~ 5-6% rare Activation loop mutations are associated with resistance to therapy Primary mutational hotspots KIT exons 9 or 11 PDGFRα
Slide 17: Proof-of-concept established for BLU-285 in advanced GIST
Proof-of-concept established for BLU-285 in advanced GIST Next steps Continue dose escalation to define an MTD and RP2D Assessment of response rate by patient sub-type Seek guidance from the FDA on the development path forward, including possibilities for expedited clinical development Part 1: Dose
Slide 18: Strong clinical activity against PDGFR D842-mutant GIST at all dose levels
Strong clinical activity against PDGFR D842-mutant GIST at all dose levels 14 out of 14 D842-mutant patients with tumor reductions All PDGFRα patients remain on treatment The values above/below the bars denote the dose level (mg) QD received by each patient. PR, partial response; PD, progressive di
Slide 19: Significant anti-tumor activity in TKI-resistant KIT-driven GIST at higher doses
Significant anti-tumor activity in TKI-resistant KIT-driven GIST at higher doses Maximum reduction – sum of diameter change from baseline (%) 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 #: off treatment BLU-285 30 – 90 mg BLU-285 135 – 300 mg 90 60 30 30 90 30 60 300 135 200 300 300 135 PD
Slide 20: BLU-285 Phase 1 study in Advanced Systemic Mastocytosis (SM)
BLU-285 Phase 1 study in Advanced Systemic Mastocytosis (SM)
Slide 21: New treatment options are needed to address the underlying cause of advanced systemic mastocytosis
New treatment options are needed to address the underlying cause of advanced systemic mastocytosis Advanced systemic mastocytosis is a rare and severe disease that shortens life expectancy with a wide range of debilitating symptoms and organ damage KIT mutation D816V is a key driver in ~90-95% of pa
Slide 22: BLU-285: Potent, highly selective KIT D816V inhibition
BLU-285: Potent, highly selective KIT D816V inhibition IC50, half maximal inhibitory concentration Kinome illustration reproduced courtesy of CSTI (cellsignal.com). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content. 22 KIT D816V Ic50 (nM) BLU-285
Slide 23: BLU-285 Phase 1 study design in advanced systemic mastocytosis
BLU-285 Phase 1 study design in advanced systemic mastocytosis Next steps Continue dose escalation to define an MTD and RP2D Assessment of response rate per international working group criteria1 and evaluation of advanced SM patient reported outcome measure by patient sub-type Evaluation of addition
Slide 24: Encouraging clinical activity with objective decreases in mast cell burden
Encouraging clinical activity with objective decreases in mast cell burden AE, adverse event; DLT, dose limiting toxicity; QD, once a day. The values above/below the bars denote the dose level (mg) QD received by each patient. Data cutoff date: November 11, 2016 24 Decreased bone marrow mast cells i
Slide 25: BLU-667
fe S = Ts) = = Kb uu (oe BLU-667
Slide 26: BLU-667 is designed as a targeted inhibitor to achieve better RET inhibition
BLU-667 is designed as a targeted inhibitor to achieve better RET inhibition ACTIVATING RET KINASE FUSIONS AND MUTATIONS ARE IMPORTANT DISEASE DRIVERS IN A VARIETY OF CANCERS Estimate ~10,000 patients in NSCLC and medullary thyroid cancer in major markets* BLU-667: DIFFERENTIATED PRODUCT PROFILE WIT
Slide 27: IND accepted for BLU-667 and study start-up underway
IND accepted for BLU-667 and study start-up underway MTD, maximum tolerated dose; MTC, medullary thyroid cancer; NSCLC, non-small cell lung cancer; PD, pharmacodynamics; PK, pharmacokinetics; RET, rearranged during transfection; RP2D, recommended part 2 dose; TKI, tyrosine kinase inhibitor 27 KEY IN
Slide 28: <= [S) <= Se ao (a,
<= [S) <= Se ao (a,
Slide 29: Developing first PRKACA-targeted inhibitor for treatment of Fibrolamellar Carcinoma
Developing first PRKACA-targeted inhibitor for treatment of Fibrolamellar Carcinoma FLC is a rare and distinct subtype of liver cancer in young adults with high medical need and no approved therapies to date Often associated with poor prognosis (5-year OS rate is 30-40%) Patient population estimated
Slide 30: Cash to fund operating expenses and capital expenditure requirements into late 2018
Cash to fund operating expenses and capital expenditure requirements into late 2018 30 SHARES OUTSTANDING as of 12/13/16 33.1 million (basic) OUTSTANDING DEBT as of 9/30/16 $4.9 million CASH, CASH EQUIVALENTS AND INVESTMENTS as of 9/30/16 $152.5 million Financial guidance gives effect to net proceed
Slide 31: Thank you
Thank you 31
Blueprint Medicines — Investor Presentation (January 2017) on 6ix